Revenue Showdown: Gilead Sciences, Inc. vs Galapagos NV

Biotech Revenue Battle: Gilead vs Galapagos

__timestamp	Galapagos NV	Gilead Sciences, Inc.
Wednesday, January 1, 2014	69368000	24890000000
Thursday, January 1, 2015	39563000	32639000000
Friday, January 1, 2016	129517000	30390000000
Sunday, January 1, 2017	127087000	26107000000
Monday, January 1, 2018	288836000	22127000000
Tuesday, January 1, 2019	844986000	22449000000
Wednesday, January 1, 2020	478053000	24689000000
Friday, January 1, 2021	484846000	27305000000
Saturday, January 1, 2022	505280000	27281000000
Sunday, January 1, 2023	239724000	27116000000

Cracking the code

Revenue Showdown: Gilead Sciences, Inc. vs Galapagos NV

In the competitive landscape of biotechnology, revenue growth is a key indicator of success. Over the past decade, Gilead Sciences, Inc. has consistently outperformed Galapagos NV in terms of revenue. From 2014 to 2023, Gilead's revenue peaked in 2015, reaching nearly 33 billion dollars, while Galapagos NV's highest revenue was approximately 845 million dollars in 2019.

Despite Galapagos NV's impressive growth, with a revenue increase of over 500% from 2014 to 2019, Gilead's revenue remained significantly higher, maintaining a steady average of around 27 billion dollars annually. This stark contrast highlights Gilead's dominant position in the market.

As we look to the future, the question remains: can Galapagos NV close the gap, or will Gilead continue to lead the charge in the biotech industry?

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025